JMIR Public Health and Surveillance (Jul 2022)

Global Pattern and Trends in Penile Cancer Incidence: Population-Based Study

  • Leiwen Fu,
  • Tian Tian,
  • Kai Yao,
  • Xiang-Feng Chen,
  • Ganfeng Luo,
  • Yanxiao Gao,
  • Yi-Fan Lin,
  • Bingyi Wang,
  • Yinghui Sun,
  • Weiran Zheng,
  • Peiyang Li,
  • Yuewei Zhan,
  • Christopher K Fairley,
  • Andrew Grulich,
  • Huachun Zou

DOI
https://doi.org/10.2196/34874
Journal volume & issue
Vol. 8, no. 7
p. e34874

Abstract

Read online

BackgroundPenile cancer is a relatively rare genital malignancy whose incidence and mortality are rising in many countries. ObjectiveThis study aims to assess the recent incidence and mortality patterns and incidence trends of penile cancer. MethodsThe age-standardized incidence and mortality rates (ASIR and ASMR, respectively) of penile cancer in 2020 were estimated from the Global Cancer Registries (GLOBOCAN) database. Incidence trends of penile cancer from 1973 to 2012 were assessed in 44 populations from 43 countries using the Cancer Incidence in Five Continents plus (CI5plus) and the Nordic Cancer Registries (NORDCAN) databases. Average annual percentage change was calculated to quantify trends in ASIR using joinpoint regression. ResultsGlobally, the estimated ASIR and ASMR of penile cancer were 0.80 (per 100,000) and 0.29 (per 100,000) in 2020, equating to 36,068 new cases and 13,211 deaths in 2020, respectively. There was no significant correlation between the ASIR (P=.05) or ASMR (P=.90) and Human Development Index. In addition, 15 countries saw increasing ASIR for penile cancer, 13 of which were from Europe (United Kingdom, Lithuania, Norway, Estonia, Finland, Sweden, Cyprus, Netherlands, Italy, Croatia, Slovakia, Russia, and the Czech), and 2 from Asia (China and Israel). ConclusionsAlthough the developing countries still bear the higher incidence and mortality of penile cancer, the incidence is on the rise in most European countries. To mitigate the disease burden resulting from penile cancer, measures to lower the risk for penile cancers, including improving penile hygiene and male human papillomavirus vaccination, may be warranted.